Results 81 to 90 of about 505,608 (261)

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Association of Severity of Posttraumatic Stress Disorder With Inflammation: Using Total White Blood Cell Count as a Marker

Chronic Stress, 2019
Background Inflammation is known to be associated with posttraumatic stress disorder. It is not known if total white blood cell count, a routinely checked inflammatory marker, is associated with posttraumatic stress disorder symptom trajectories using ...
Farrukh M. Koraishy, Joanne Salas, Thomas C. Neylan, Beth E. Cohen, Paula P. Schnurr, Sean Clouston, Jeffrey F. Scherrer   +6 more
doaj   +1 more source

Which blood tests are most helpful in evaluating pelvic inflammatory disease? [PDF]

, 2004
No individual or combination of blood tests can reliably diagnose pelvic inflammatory disease (PID)(strength of recommendation [SOR]: A, metaanalysis).
Hall, Mary N., Leach, Laura
core  

Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation [PDF]

, 1986
Twenty‐seven clinical and laboratory data and the subsequent clinical course of 93 consecutive adult patients who underwent orthotopic liver transplantation for various chronic advanced liver diseases were analyzed retrospectively to assess the risk ...
Child, Christensen, Christensen, Cuervas-Mons, Doberneck, Lewis, Orrego, Romeder, Sox, Starzl, Starzl, Van Thiel, Van Thiel, Van Thiel   +13 more
core   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Red blood cell count as an indicator of microvascular complications in Chinese patients with type 2 diabetes mellitus

Vascular Health and Risk Management, 2013
Zhan-Sheng Wang,1,2 Zhan-Chun Song,1 Jing-Hui Bai,1 Fei Li,3 Tao Wu,1 Ji Qi,2 Jian Hu11Department of Cardiology, First Affiliated Hospital of China Medical University, 2Second Department of Cardiology, Fourth People's Hospital of Shenyang, Shenyang ...
Wang ZS, Song ZC, Bai JH, Li F, Wu T, Qi J, Hu J   +6 more
doaj  

Drugs for preventing red blood cell dehydration in people with sickle cell disease. [PDF]

, 2018
BACKGROUND: Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications.
Ballas, Samir K., Nagalla, Srikanth
core   +1 more source

Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption [PDF]

, 2008
Background The advantage of treatment interruptions (TIs) in salvage therapy remains controversial. Regardless, characterizations of the correlates of CD4 count fall during TI are important to identify since patients with virologic ...
Kenneth H Huang, Mona R Loutfy, Christos M Tsoukas, Nicole F Bernard, FJ Palella Jr., SG Deeks, C Katlama, J Lawrence, WM El Sadr, J Gamberg, MS Topp, JM Brenchley, BE Palmer, SA Migueles, SA Younes, RD Schrier, F Garcia, A Boschi, R Thiebaut, B Ledergerber, A Harari   +20 more
core   +3 more sources